Invion Ltd. · ASX:IVX
Invion — AusBioInvest 2022
23 slides from Invion's conference presentation, Oct 27, 2022
Slide 1: ASX Announcement: Invion Conference Presentation
ASX ANNOUNCEMENT INVION CONFERENCE PRESENTATION For personal use only MELBOURNE (AUSTRALIA) 27 October 2022: Invion Limited (ASX: IVX) (“Invion” or the “Company”) will be presenting at AusBioInvest 2022 in Perth today. Invion’s Executive Chairman and Chief Executive Officer, Thian Chew, will be usin
Slide 2: AusBioInvest 2022 Presentation
For personal use only AUSBIOINVEST 2022 PRESENTATION October 2022
Slide 3: Disclaimer
DISCLAIMER For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Invion Limited (Company). In p
Slide 4: Company Overview: Developing the Next-Gen Photodynamic Therapy
COMPANY OVERVIEW DEVELOPING THE NEXT-GEN PHOTODYNAMIC THERAPY (PDT) For personal use only Major disease areas: Cancer + atherosclerosis and infectious diseases (AID) Meeting Clinical Advancing Photosoft™ technology – novel PDT photosensitiser INV043 Needs Collaboration with world-class experti
Slide 5: The Photosoft Advantage: A Novel Cancer Treatment
THE PHOTOSOFTTM ADVANTAGE A NOVEL CANCER TREATMENT For personal use only NGPDT (Next-Gen PDT) is a ground-breaking NGPDT is a minimally invasive modality for technology that overcomes many of the treating cancer that specifically identifies and shortcomings of early PDT technologies and destroys can
Slide 6: Lead Cancer Drug Candidate INV043
LEAD CANCER DRUG CANDIDATE INV043 PATHWAY TO A US$271B MARKET OPPORTUNITY1 For personal use only Proof-of-Concept studies of lead candidate INV043 has been shown to: Selectively absorbed by cancer cells and not healthy tissue Invion is leading the Effective in regressing multiple types of cancer in
Slide 7: Key Partnerships: World-Leading Institutions
KEY PARTNERSHIPS WORLD-LEADING INSTITUTIONS For personal use only • Global bioscience medical research institute • World-class institute that combines its premier • Over 400 scientists focused on ground-breaking cancer research capability with its ability to discoveries addressing complex problems i
Slide 8: Cancer Findings
For personal use only Cancer Findings Proof-of-Concept Studies on INV043
Slide 9: Improved API: INV043 Key Characteristics
IMPROVED API: INV043 KEY CHARACTERISTICS* For personal use only Active against multiple cancers Highly potent and selective INV034 activity against multiple cancer cell types • INV043 successfully regressed • ~600x greater photoxicity established T-cell lymphoma, than Talaporfin sodium (a triple neg
Slide 10: Proof of Concept: Primary Tumour Pilot Study
PROOF OF CONCEPT: PRIMARY TUMOUR PILOT STUDY REGRESSION AND PROTECTIVE IMMUNITY For personal use only Treatment with established tumours (INV043 with light) • INV043 was injected intratumorally (0.1mg/kg) • 16 hours later, illuminated with red light • No anaesthesia required, no adverse effects obse
Slide 11: Proof of Concept: Primary Tumour Pilot Study
PROOF OF CONCEPT: PRIMARY TUMOUR PILOT STUDY REGRESSION AND PROTECTIVE IMMUNITY For personal use only • Triple Negative Breast Cancer (TNBC) is a hard-to-treat cancer resistant to most chemotherapies • Proof of Concept (PoC) pilot showed complete regression of TNBC in vivo following INV043 treatment
Slide 12: Anal Cancer SCC: Promising Results Against New Cancer Class
ANAL CANCER SCC PROMISING RESULTS AGAINST NEW CANCER CLASS* For personal use only Cytotoxicity data of human anal SCC cells lines In vitro study showed INV043’s effectiveness against six squamous cell carcinoma (SCC) cell lines that represent the full range of anal cancers Most anal cancers are SCCs
Slide 13: Proof of Concept: Immune Checkpoint Inhibitors Combination Therapy
PROOF OF CONCEPT: IMMUNE CHECKPOINT INHIBITORS (ICI) COMBINATION THERAPY FOR A US$140B MARKET1 (BY 2030) For personal use only • Immune checkpoint inhibitors are widely used for the treatment of lung cancer and melanoma. However, ICI treatments are typically only effective on a small proportion of p
Slide 14: Infectious Diseases
For personal use only Infectious Diseases Exploring the potential applications of PhotosoftTM
Slide 15: Broad-Spectrum Anti-Microbial Potential
BROAD-SPECTRUM ANTI-MICROBIAL POTENTIAL INFECTIOUS DISEASES: EFFECTIVE AGAINST VIRUSES, BACTERIA AND FUNGI IN VITRO For personal use only “Antimicrobial resistance (AMR) is one of the top 10 threats facing humanity” World Health Organisation1 Leading Institutions: Viroclinics conducted virus “ tests
Slide 16: Effective Against SARS-CoV-2 In Vitro
EFFECTIVE AGAINST SARS-CoV-2 IN VITRO ANTIVIRAL ACTIVITY AGAINST DELTA AND OMICRON VARIANTS For personal use only SARS-CoV-2: Delta Selected PhotosoftTM Compounds vs. Remdesivir 100 Nine out of ten PhotosoftTM compounds tested displayed antiviral activity against both Delta 80 % Inhibition and Omicr
Slide 17: Effective Against Zika and Dengue In Vitro
EFFECTIVE AGAINST ZIKA AND DENGUE IN VITRO ANTIVIRAL ACTIVITY AGAINST ZIKA AND DENGUE For personal use only Zika Dengue Inhibition: PhotosoftTM compound vs Monensin1 Inhibition: Selected PhotosoftTM Compounds vs Monensin1 100 100 90 90 Percentage (%) inhibition 80 80 70 70 % Inhibition 60 60 50 50 4
Slide 18: Effective Against Bacteria and Fungi
EFFECTIVE AGAINST BACTERIA AND FUNGI MRSA SUPERBUG, E.COLI BACTERIA & CANDIDA ALBICANS FUNGUS For personal use only Broad Spectrum Activity: Minimum Inhibition Several PhotosoftTM compounds showed Concentration (MIC50) of Selected Photosoft Compound following exposure to light for 5 minutes activi
Slide 19: The Way Forward: Multiple Catalysts and Milestones
THE WAY FORWARD MULTIPLE CATALYSTS AND MILESTONES For personal use only Australia • Proof of Concept (PoC) Building on in vivo work further demonstrating both safety and efficacy profiles • Pre-clinical Preparations: Building foundations for clinical trials in multiple indications and internationall
Slide 20: Management Team
MANAGEMENT TEAM THE RIGHT EXPERTISE FOR SUCCESS For personal use only THIAN CHEW MELANIE LEYDIN EXECUTIVE CHAIRMAN & CEO CFO • Managing Partner, Polar Ventures • 25+ years in accounting profession • Executive Director, Goldman Sachs • Partner, Vistra • Director, KPMG Consulting, Senior Manager KPMG
Slide 21: Summary
SUMMARY For personal use only Cancer - Promising Results: Infectious Diseases – Early Findings: Total tumour regression, In vitro effectiveness against multiple immune response, potential ICI viruses & bacteria including SARS-CoV- combination therapies 2 (Delta and Omicron) and MRSA Cancer - Clinica
Slide 22: Market Overview
YTD Share Price* MARKET OVERVIEW $0.012 For personal use only (as of 03 Oct 2022) Market Cap A$77m Clinical-stage life sciences TOP 10 SHAREHOLDERS %IC company developing the Focus PhotosoftTM technology as Polar Ventures Limited 8.49 a treatment for a range of BNP Paribas Nominees Pty Ltd 7.99 dise
Slide 23: For personal use only
For personal use only